Wallace, K., Goble, S., Isaacson, J., Maloney, L., Cameron, T., & Bedel, J. (2019). Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”. Pharmacoeconomics.
Citação norma ChicagoWallace, Katrine, Sandra Goble, Jeff Isaacson, Lara Maloney, Terri Cameron, and Josh Bedel. "Comment On: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients With Ovarian Cancer in the United States”." Pharmacoeconomics 2019.
Citação norma MLAWallace, Katrine, et al. "Comment On: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients With Ovarian Cancer in the United States”." Pharmacoeconomics 2019.